Back to Portfolio
Status
Current
65 Equity Partners has invested in a premier oncology and cardiology group in Asia (the “Platform”), encompassing the medical practices set out below.
OncoCare Medical (“OncoCare”) is one of the largest private oncology practices in Singapore, providing comprehensive consulting, diagnosis, and treatment services across various subspecialties.
Novena Heart Centre (“NHC”) is one of the leading multi-disciplinary cardiology group practices in Singapore, specializing in coronary intervention, heart rhythm management, heart failure, cardiac imaging, and cardiothoracic surgery.
Since our investment in the Platform, the Platform has further acquired 3 other assets, including Singapore Breast Surgery Center (“SBSC”), Central Luzon Integrated Oncology Centre (“CLIOC”) and Can-Care.
SBSC is an integrated breast cancer care group in Singapore, operating under the brands Solis and Luma, covering the entire breast cancer theragnostic process, including screening, diagnostic imaging, pathology and surgery services.
CLIOC is a leading oncology clinic located in Mother Teresa of Calcutta Medical Center in San Fernando, Philippines, providing tomotherapy and chemotherapy services.
Can-Care is a retailer and distributor of post-cancer care products, operating out of four retail outlets in Singapore and Malaysia, as well as 22 distributor outlets in various jurisdictions.
Who we partnered with
65 Equity Partners partnered with Templewater, a Hong Kong-based private equity firm, on the establishment of the Platform and its initial acquisition of OncoCare and NHC. 65 Equity Partners is dedicated to collaborating closely with doctors and management to maintain the Platform’s high standards and support its international expansion.
What attracted us to the business
The Platform has quality business fundamentals stemming from its market leading practices and specialists. It is well-positioned to capitalize on the regional secular tailwinds of an aging population, the rise in private healthcare spending, and Singapore’s status as a leading medical hub. We are excited about the opportunity to work with our shareholder partner and doctors to grow the group into a leading regional healthcare platform headquartered in Singapore.
Our value creation strategy
We aim to leverage our connections in the Singapore and Southeast Asia healthcare sector as well as our international market access to support both organic and inorganic growth initiatives, to enhance operations, and to build a leading specialty healthcare platform delivering best-in-class healthcare services to an even broader patient base in the region.
Website
https://www.novenaheartcentre.com.sg/